Monday, November 16, 2026 | 04:16 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 4 - Q2 Results

Aurobindo Pharma Q2 net down 41% to Rs 409 cr, revenue dips to Rs 5,739 cr

Aurobindo Pharma on Saturday reported a 41 per cent decline in its consolidated net profit at Rs 409 crore for the second quarter ended September 30, 2022. The Hyderabad-based drug firm had posted a net profit of Rs 697 crore in the July-September period of last fiscal. Revenue from operations also declined to Rs 5,739 crore in the September quarter as against Rs 5,942 crore in the year-ago period. Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy said the company's second quarter performance was subdued, mainly due to macro-environment factors and higher competitive intensity for some products in the US. "However, we are confident that our robust pipeline of new products will provide impetus to the future growth trajectory," he added. Reddy noted that company's continued focus on biosimilars, R&D, innovation and increasing manufacturing capacity will enhance its product offerings in various markets. "We are confident that, the right measures and growth-le

Aurobindo Pharma Q2 net down 41% to Rs 409 cr, revenue dips to Rs 5,739 cr
Updated On : 12 Nov 2022 | 7:50 PM IST

IREDA Q2 net profit surges 67% to Rs 184 crore on higher revenues

The Indian Renewable Energy Development Agency (IREDA) on Saturday posted 67 per cent jump in net profit at Rs 184.30 crore for September quarter 2022-23, mainly due to higher revenues. In the year-ago period, the profit after tax was Rs 110.27 crore, according to a statement from Ministry of New & Renewable Energy. Gross income rose to Rs 791.56 crore from Rs 682.94 crore. IREDA's Net Non-Performing Assets (bad loans) were reduced to 2.72 per cent in the quarter under review from 4.87 per cent in the same period a year ago. Its loan book stood at Rs 33,783.36 crore in the quarter as against Rs 28,856.48 crore earlier. The agency sanctioned loans of Rs 11,226.49 crore in the quarter as compared with Rs 5,925.12 crore in the same period a year ago.

IREDA Q2 net profit surges 67% to Rs 184 crore on higher revenues
Updated On : 12 Nov 2022 | 6:58 PM IST

RITES Q2 PAT drops 20% to Rs 140 crore, income declines to Rs 684 crore

RITES Ltd, a public sector transport consultancy and engineering firm, has reported 19.6 per cent decline in consolidated profit after tax (PAT) at Rs 140.20 crore for September quarter 2022-23. The company had logged a PAT of Rs 174.49 crore in the year-ago period, RITES said in a BSE filing on Friday. Income dropped to Rs 684.30 crore from Rs 788.85 crore in the year-ago period. "The trend of sequential growth as also seen vis-a-vis H1 (April-September) of the previous year continues despite a dip in the export stream of revenue. "The results reiterate our core strength and the USP (unique selling point) of having a diversified business portfolio," Chairman and Managing Director Rahul Mithal said. RITES is a miniratna public sector enterprise and a leading player in the transport consultancy and engineering sector in the country.

RITES Q2 PAT drops 20% to Rs 140 crore, income declines to Rs 684 crore
Updated On : 12 Nov 2022 | 5:12 PM IST

JB Chemicals & Pharma Q2 PAT up 13% to Rs 111 cr; revenue at Rs 809 cr

JB Chemicals & Pharmaceuticals has reported 13 per cent rise in profit after tax at Rs 111 crore for the second quarter ended September 30, 2022. The drug firm had logged a profit after tax (PAT) of Rs 98 crore in July-September period of previous fiscal year. Revenue rose to Rs 809 crore in the period under review as compared with Rs 593 crore in the year-ago quarter, it said in a statement. "Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period," company CEO and Wholetime Director Nikhil Chopra said. The momentum in the international business continued across markets, with all three of the company's verticals performing well, he added. "Our strategic focus on key brands, segments and geographies is resulting in a consistent, sustained revenue growth. "And this growth, along with ...

JB Chemicals & Pharma Q2 PAT up 13% to Rs 111 cr; revenue at Rs 809 cr
Updated On : 12 Nov 2022 | 3:33 PM IST

Ashok Leyland posts Rs 199 crore net profit in Q2, revenue up 85% YoY

The company has also achieved a market share of 32 per cent in Q2FY23

Ashok Leyland posts Rs 199 crore net profit in Q2, revenue up 85% YoY
Updated On : 12 Nov 2022 | 12:53 AM IST

Adani Power Q2 results: Revenue rises 36%, net profit at Rs 696 crore

Consolidated revenue in Q2 rose 36 per cent year-on-year (YoY) to Rs 7,044 crore due to improved tariff realisation and higher one-time income of Rs 771 crore

Adani Power Q2 results: Revenue rises 36%, net profit at Rs 696 crore
Updated On : 12 Nov 2022 | 12:08 AM IST

Strong SUV sales bump up M&M's Q2 net by 46% YoY to Rs 2,090 crore

Revenue during the period rose 57% to Rs 20,839 crore from Rs 13,314 crore

Strong SUV sales bump up M&M's Q2 net by 46% YoY to Rs 2,090 crore
Updated On : 11 Nov 2022 | 11:25 PM IST

Hindalco Q2 profit falls 36% on high energy costs, lower aluminium prices

Consolidated earnings before interest tax depreciation and amortisation (Ebitda) declined by 29 per cent YoY in Q2 to Rs 5,743 crore on higher input costs

Hindalco Q2 profit falls 36% on high energy costs, lower aluminium prices
Updated On : 11 Nov 2022 | 11:22 PM IST

ABB India net up 69% to Rs 203 cr in July-Sept quarter on higher revenues

Electrification and automation major ABB India on Friday posted a 69 per cent rise in consolidated net profit to Rs 203 crore in the September quarter, aided by higher revenues and a one-off gain. The consolidated net profit of the company stood at Rs 120 crore in the quarter ended September 30, 2021. "Profit after tax reported at Rs 203 crores, a growth of 69 per cent over Q3 2021 (July-September 2021) driven by solid execution after considering a one-time extraordinary gain (Rs 46 Crores) on the final divestment of the turbo charger business," a company statement said. The company follows the January to December financial year. Its revenues rose to Rs 2,120 crore in the quarter from Rs 1,778 crore in the same period a year ago. Total orders for the quarter were at Rs 2,634 crore as compared to Rs 1,909 crore in Q3 2021 (July-September 2021), a growth of 38 per cent. Process automation spearheaded performance, with wins from large conglomerates in steel, cement, gas, resulting i

ABB India net up 69% to Rs 203 cr in July-Sept quarter on higher revenues
Updated On : 11 Nov 2022 | 11:22 PM IST

LIC sees multifold increase in Q2 net profit at Rs 15,952 crore

This is due to transfer of funds from non-par to shareholders' account

LIC sees multifold increase in Q2 net profit at Rs 15,952 crore
Updated On : 11 Nov 2022 | 11:14 PM IST

Nykaa gets a thumbs up from investors after a strong Q2 performance

Further gains in margins and growth acceleration in the fashion section are potential triggers

Nykaa gets a thumbs up from investors after a strong Q2 performance
Updated On : 11 Nov 2022 | 10:57 PM IST

Zomato soars 13% on heavy volume as net loss narrows to Rs 251 cr in Q2

The company's revenue, too, increased 62.2 per cent year-on-year (YoY) to Rs 1,661 crore in Q2FY23 as against Rs 1,024 crore in Q2FY22

Zomato soars 13% on heavy volume as net loss narrows to Rs 251 cr in Q2
Updated On : 11 Nov 2022 | 10:53 PM IST

Metal stocks rally despite decline in corporate earnings in Sept quarter

Bright future for sector could be a reason, say experts

Metal stocks rally despite decline in corporate earnings in Sept quarter
Updated On : 11 Nov 2022 | 10:44 PM IST

Glenmark Pharmaceuticals Q2 PAT rises marginally to Rs 279 crore

Glenmark Pharmaceuticals on Friday said its profit after tax (PAT) rose marginally to Rs 279 crore for the second quarter ended September 30, 2022. The Mumbai-based drug firm had reported a PAT of Rs 275 crore in the July-September period of the previous fiscal. Consolidated revenue rose to Rs 3,375 crore in the period under review as against Rs 3,147 crore in the year-ago quarter, Glenmark Pharma said in a regulatory filing. "We delivered yet another quarter of consistent growth, with our relentless focus on launching differentiated products in our core therapeutic areas," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said. The company's domestic business recorded strong double-digit growth and Europe business also performed very well in spite of a challenging macro-economic environment, he added. "We look forward to launching new products across markets and building global scale in our respiratory portfolio," Saldanha said.

Glenmark Pharmaceuticals Q2 PAT rises marginally to Rs 279 crore
Updated On : 11 Nov 2022 | 10:05 PM IST

ITI Limited Q2 loss widens to Rs 100 cr, revenue plunges 44% to Rs 197 cr

State-owned telecom gear maker ITI Limited on Friday reported widening of its consolidated net loss to over Rs 100 crore in the second quarter ended September 30, 2022. The company had posted a loss of Rs 55.8 crore in the same period a year ago. The revenue from operations of ITI plunged by about 44 per cent to Rs 197.55 crore during the reported quarter from Rs 352.49 crore in the year ago period. According to the auditor's note, the company had to bear the financial burden of granting a voluntary retirement scheme (VRS) to employees in 2019-20 after the Department of Telecommunications refused to accept the proposal of granting VRS on medical grounds. The auditor note said that the ITI has not made any provision for credit losses amount to Rs 96.1 crore under trade receivables comprising Rs 58.47 crore from C-DoT, Rs 16.9 crore from HCL Infosystems, Rs 10.49 crore from HFCL and Rs 10.23 crore from Mind Array, which are doubtful recoveries.

ITI Limited Q2 loss widens to Rs 100 cr, revenue plunges 44% to Rs 197 cr
Updated On : 11 Nov 2022 | 10:04 PM IST

LIC Q2 results: PAT rises 11-fold to Rs 15,952 crore; net income up 26%

The net income from investments for Q2 stood at Rs 84,103.64 crore, as compared to Rs 76,533.75 crore in the year-ago period

LIC Q2 results: PAT rises 11-fold to Rs 15,952 crore; net income up 26%
Updated On : 11 Nov 2022 | 9:39 PM IST

Ircon International Q2 net up 38% to Rs 174 cr, income rises to Rs 2,305 cr

Ircon International Ltd on Friday reported a 38.3 per cent rise in its consolidated net profit at Rs 174.18 crore for the quarter ended September 30, 2022. The company had posted a consolidated net profit of Rs 125.94 crore in the year-ago period, Ircon International said in a filing to BSE. The consolidated income of the company during the second quarter increased to Rs 2,305.87 crore from Rs 1,582.67 crore in the year-ago period. Ircon International is a government of India undertaking under the Ministry of Railways.

Ircon International Q2 net up 38% to Rs 174 cr, income rises to Rs 2,305 cr
Updated On : 11 Nov 2022 | 9:18 PM IST

Suryoday SFB reports Rs 13-cr Q2 net against Rs 1.92-cr loss a year ago

On a sequential basis, the bank's net profit rose 67.7 per cent from Rs 7.75 crore in April-June

Suryoday SFB reports Rs 13-cr Q2 net against Rs 1.92-cr loss a year ago
Updated On : 11 Nov 2022 | 8:12 PM IST

Fortis Healthcare sees strong growth in hospital revenues in Q2FY23

Q2FY23 hospital business revenues stood at Rs 1,297 crore versus Rs 1,098.5 crore in Q2FY22 and Rs 1,192.4 crore in Q1FY23

Fortis Healthcare sees strong growth in hospital revenues in Q2FY23
Updated On : 11 Nov 2022 | 8:00 PM IST

Alembic Pharma Q2 net profit dips 19% to Rs 133 crore on higher expenses

Alembic Pharmaceuticals on Friday said its consolidated net profit declined by 19 per cent to Rs 133 crore for the second quarter ended September 2022 on account of higher expenses. The drug maker had reported a net profit of Rs 164 crore in the July-September period of last fiscal. Revenue from operations rose to Rs 1,475 crore in the September quarter as against Rs 1,292 crore in the year-ago period, Alembic Pharmaceuticals said in a regulatory filing. Expenses during the period under review stood at Rs 509 crore as compared to Rs 428 crore earlier. "It was a satisfactory quarter led by growth in all the verticals of the company, in particular the API business outperformed with a 23 per cent growth during the quarter," Alembic Pharmaceuticals Managing Director Pranav Amin said in a regulatory filing. Shares of the company on Friday ended 3.68 per cent up at Rs 638.75 apiece on the BSE.

Alembic Pharma Q2 net profit dips 19% to Rs 133 crore on higher expenses
Updated On : 11 Nov 2022 | 6:56 PM IST